- Home
- FRAF vs PROK Comparison
FRAF vs PROK Comparison
Compare FRAF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRAF | PROK |
|---|---|---|
| Founded | 1906 | 2015 |
| Country | United States | United States |
| Employees | 306 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.0M | 316.0M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FRAF | PROK |
|---|---|---|
| Price | $61.85 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 23.1K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | ★ 88.84 | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $21.12 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $43.47 | $1.30 |
| 52 Week High | $65.41 | $3.48 |
Technical Indicators
Market Signals| Indicator | FRAF | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 52.22 |
| Support Level | $60.31 | $1.56 |
| Resistance Level | $64.19 | $2.59 |
| Average True Range (ATR) | 1.57 | 0.11 |
| MACD | -0.24 | 0.00 |
| Stochastic Oscillator | 27.40 | 72.50 |
Price Performance
Historical ComparisonAbout FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.